INTRADERMAL BOTULINUM TOXIN FOR ERYTHEMATOTELANGIECTATIC ROSACEA: MECHANISMS, DOSING AND SAFETY
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.6141Keywords:
Erythematotelangiectatic Rosacea; Botulinum Toxin Type A; Intradermal Injection; Microbotox; Microdroplet Technique; VEGF; Neurogenic InflammationAbstract
Erythematotelangiectatic rosacea is a chronic inflammatory and neurovascular facial dermatosis characterized by persistent centrofacial erythema, flushing, telangiectasia, burning, stinging, and marked impairment of quality of life. Although topical alpha-adrenergic agonists, vascular lasers, intense pulsed light, systemic anti-inflammatory agents, and skin barrier-directed interventions are widely used, persistent erythema and flushing often remain difficult to control. Intradermal botulinum toxin type A has emerged as a promising off-label therapeutic option for refractory vascular rosacea. Its effect is no longer interpreted solely through neuromuscular blockade. Current evidence suggests that botulinum toxin type A may reduce erythema and flushing through modulation of acetylcholine-dependent vasodilation, inhibition of vasoactive neuropeptides such as substance P and calcitonin gene-related peptide, suppression of mast cell degranulation, interference with LL-37/MRGPRX2-mediated inflammation, downregulation of vascular endothelial growth factor-driven angiogenesis, and improvement of skin quality parameters including sebum production and pore appearance. Clinical studies, including case series, prospective cohorts, split-face trials, and meta-analyses, indicate reductions in erythema, flushing severity, vascular density, and patient-reported symptoms after intradermal or microdroplet injections. However, the literature remains limited by small sample sizes, heterogeneous dosing regimens, short follow-up, variable toxin formulations, and inconsistent outcome measures. This review summarizes the mechanistic rationale, clinical efficacy, injection protocols, safety profile, limitations, and future directions of intradermal botulinum toxin type A in erythematotelangiectatic rosacea.
References
Alsaati, A. A., Alsaadoun, D., Kinkar, L. I., Alkhamis, R. S., Ahmed, W. A., & Almathami, A. H. (2023). The efficacy and safety of botulinum toxin A for the treatment of rosacea: A systematic review. Cureus, 15(12). https://doi.org/10.7759/cureus.51304
Anatomical exhortations of botulinum toxin injections for rosacea | Journal of Clinical and Aesthetic Dermatology | Professor Faisal Ali. (n.d.). Retrieved June 14, 2026, from https://www.dralidermatology.com/publications/anatomical-exhortations-of-botulinum-toxin-injections-for-rosacea-journal-of-clinical-and-aesthetic-dermatology/
Bharti, J., Sonthalia, S., & Jakhar, D. (2023). Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. Journal of the American Academy of Dermatology, 88(6), e295–e296. https://doi.org/10.1016/j.jaad.2018.05.014
Buchholz, E., Wanitphakdeedecha, R., Jaturawichanant, S., Pattanapran, K., & Corduff, N. (2025). Hypersensitivity reactions associated with aesthetic botulinum toxin A injections: A case series. Cureus, 17(10), e95795. https://doi.org/10.7759/cureus.95795
Calvisi, L., Diaspro, A., & Sito, G. (2022). Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. Journal of Cosmetic Dermatology, 21(9), 3747–3753. https://doi.org/10.1111/jocd.14692
Choe, J., & Barbieri, J. S. (2023). Emerging medical therapies in rosacea: A narrative review. Dermatology and Therapy, 13(12), 2933–2949. https://doi.org/10.1007/s13555-023-01048-1
Choi, J. E., Werbel, T., Wang, Z., Wu, C. C., Yaksh, T. L., & Di Nardo, A. (2019). Botulinum toxin blocks mast cells and prevents rosacea-like inflammation. Journal of Dermatological Science, 93(1), 58–64. https://doi.org/10.1016/j.jdermsci.2018.12.004
Daǧtaş, B. B., Erdem, O., Gneç, T. İ., Avci, E. B., Manav, V., & Koku Aksu, A. E. (2025). Effects of botulinum toxin type A treatment on clinical and biophysical parameters in patients with erythematotelangiectatic rosacea: A prospective, randomized, controlled, double-blind study. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 51(5), 515–521. https://doi.org/10.1097/dss.0000000000004528
DeLuca-Pytell, D., Dass, K., Audia, G., & Busuito, E. (2026). Serum sickness after cosmetic botulinum toxin type A injections. Aesthetic Surgery Journal Open Forum, 8. https://doi.org/10.1093/asjof/ojag027
Dicker, V., Serna Posada, M. del M., Galeano Piedrahita, E., Vasquez Villegas, S., & Perez Madrid, C. (2025). Intradermal microdroplet injection of standard-diluted incobotulinumtoxin A for the treatment of erythematotelangiectatic rosacea: A study from a dermatology center in Medellín, Colombia. Cureus. https://doi.org/10.7759/cureus.78957
Fabi, S. G., Park, J. Y., Goldie, K., & Wu, W. (2023). Microtoxin for improving pore size, skin laxity, sebum control, and scars: A roundtable on integrating intradermal botulinum toxin type A microdoses into clinical practice. Aesthetic Surgery Journal, 43(9), 1015–1024. https://doi.org/10.1093/asj/sjad044
Hanna, E., Xing, L., Taylor, J. H., & Bertucci, V. (2022). Role of botulinum toxin A in improving facial erythema and skin quality. Archives of Dermatological Research, 314(8), 729–738. https://doi.org/10.1007/s00403-021-02277-0
Kandhari, R., Kaur, I., Gupta, J., & Al-Niaimi, F. (2022). Microdroplet botulinum toxin: A review. Journal of Cutaneous and Aesthetic Surgery, 15(2), 101–107. https://doi.org/10.4103/jcas.jcas_162_21
Li, Y., Zheng, Q., Lin, J., Su, X., Zhuang, J., Wei, Q., & Hu, J. (2024). Mild allergic reactions after botulinum toxin injection: A case series and literature review. Plastic and Reconstructive Surgery Global Open, 12(5), e5845. https://doi.org/10.1097/gox.0000000000005845
Marrar, K., Althiyabi, R., Alsannaa, M., Alfalah, R., Soroje, J., Anbar, E., Al Ibrahim, I., & Al Awadhi, A. (2026). Therapeutic efficacy and safety of botulinum toxin type A in erythematotelangiectatic rosacea: A systematic review. Cureus, 18(4). https://doi.org/10.7759/cureus.106841
Nazari, S., Sadeghi, M. S., Pourani, M. R., Muñoz-Gonzalez, C., & Fakih-Gomez, N. (2026). Botulinum toxin vascular effectiveness: Low or high doses? Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-026-05685-7
Nguyen, T. T., Le, D. H., Vu, H. T., Vu, L. H., Vu, M. N., & Pham, P. T. M. (2026). Combination therapy with oral doxycycline and intradermal botulinum toxin type A for moderate-to-severe rosacea: A randomized controlled trial. Indian Journal of Dermatology, 71(2). https://doi.org/10.4103/ijd.ijd_654_24
Santillan, M. R., Ozog, D., & Wu, W. (2024). Using neuromodulators to improve scar formation, keloids, rosacea, and antiaging. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 50(9S), S91–S96. https://doi.org/10.1097/dss.0000000000004353
Sharma, A., Kroumpouzos, G., Kassir, M., Galadari, H., Goren, A., Grabbe, S., & Goldust, M. (2022). Rosacea management: A comprehensive review. Journal of Cosmetic Dermatology, 21(5), 1895–1904. https://doi.org/10.1111/jocd.14816
Takahashi, K. H., Utiyama, T. O., Bagatin, E., Picosse, F. R., & Almeida, F. A. (2024). Efficacy and safety of botulinum toxin for rosacea with positive impact on quality of life and self-esteem. International Journal of Dermatology, 63(5), 590–596. https://doi.org/10.1111/ijd.17040
Tam, E., Choo, J. P. S., Rao, P., Webb, W. R., Carruthers, J. D. A., & Rahman, E. (2025). A systematic review on the effectiveness and safety of combining biostimulators with botulinum toxin, dermal fillers, and energy-based devices. Aesthetic Plastic Surgery, 49(10), 2809–2833. https://doi.org/10.1007/s00266-024-04627-5
Tong, Y., Luo, W., Gao, Y., Liu, L., Tang, Q., & Wa, Q. (2022). A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea. Dermatologic Therapy, 35(5). https://doi.org/10.1111/dth.15395
Vincent, N., Ravipati, A., Reynolds, J. M., & Kaufman, J. (2024). Efficacy of botulinum toxin in the treatment of cutaneous flushing: A systematic review and meta-analysis. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 50(4), 354–359. https://doi.org/10.1097/dss.0000000000004073
Wan, J., Le, Y., Geng, M. M., Dong, B. Q., Liao, Z. K., Liu, L. X., & Lei, T. C. (2025). The anti-angiogenic effect of microbotox on rosacea is due to the suppressed secretion of VEGF by mast cells resulting from internalization of the MRGPRX2 receptor. Annals of Dermatology, 37(4), 228–240. https://doi.org/10.5021/ad.24.171
Yang, R., Liu, C., Liu, W., Luo, J., Cheng, S., & Mu, X. (2022). Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea. Dermatology and Therapy, 12(10), 2285–2294. https://doi.org/10.1007/s13555-022-00784-0
Yeh, M. C. H., Shih, Y. C., & Huang, Y. C. (2025). Intradermal injection of botulinum toxin for erythema in rosacea: A scoping review and meta-analysis. Indian Journal of Dermatology, Venereology and Leprology, 91(4), 448–454. https://doi.org/10.25259/ijdvl_274_2024
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aleksandra Kujach, Julia Góralska, Melania Popielarczyk, Katarzyna Napiórkowska, Dominik Płaza
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
